Sign In
Media & Investors
Skip Navigation LinksSanten > EMEA > Media & Investors > News > Santen launches TAFLOTAN® in Russia

Santen Pharmaceutical welcomes your inquiries and opinions.

Santen launches TAFLOTAN® in Russia

St. Petersburg – May 27, 2014. Santen Europe announces the launch of Taflotan® (generic name: tafluprost), the first* preservative-free prostaglandin for reduction of intraocular pressure in open angle glaucoma and ocular hypertension. Today’s launch symposium at international conference “White Night” in St. Petersburg officially celebrates the market entry of Taflotan® in Russia.


Currently, the only proven method for the treatment of glaucoma is to lower the intraocular pressure (IOP), which is the most common risk factor for glaucoma. Taflotan® is effective in the reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension.


Moreover Taflotan® is expected to offer benefits for patients who suffer from side effects of glaucoma eye drops with preservatives, especially patients with dry/sensitive eyes. Taflotan® can be used as a monotherapy with patients who would benefit from preservative-free prostaglandin eye drops, who are insufficiently responsive to first line treatment or are intolerant or contra-indicated to first line treatment. It can also be used as additional treatment to beta-blockers.


Glaucoma is a common eye disease, with an estimated number of 67 million glaucoma patients in the world and occurring predominantly in people aged over 60. It causes damage to the optic nerve, resulting in visual loss and if untreated it may lead to blindness. Even in developed countries the majority of patients remain undiagnosed. Therefore, diagnosis of glaucoma remains an important issue.


*since June 2008 on the market

About Santen

Founded in 1890, Santen is a global company headquartered in Osaka, Japan.  Santen researches, develops and markets ophthalmic products for physicians worldwide.  Santen currently delivers valuable ophthalmology products meeting the unmet medical needs to more than 50 countries and regions worldwide.  Among prescription ophthalmic pharmaceuticals, Santen holds the top share within the Japanese market and is one of the leading ophthalmic companies worldwide. Based on its corporate values, Santen is committed to contribute to patients and their loved ones, and consequently to the society by focusing its efforts on ophthalmology and related areas. Tokyo Stock Exchange code: 4536. For more information, visit


Santen Media contact
Geneviève Garrigos
Corporate Communication Director - Europe
Tel: +33-6-6554-6019